

IOWA Provider Services

1 (844) 236-1464

PAA-1098

Request for Prior Authorization



SEDATIVE/HYPNOTICS-NON-BENZODIAZEPINE

(PLEASE PRINT – ACCURACY IS IMPORTANT)

FAX Completed Form To 1 (877) 733-3195

IA M	edia	hie	Mem	her	ח#				Pat	ient name					DOB
		Juid				ĺ			. at						
Patie	nt a	ddre	ess												
Provi	der	NP	I							Prescriber name					Phone
Preso	rib	er ad	ddres	ss											Fax
Phar	nac	y na	me						Ad	dress					Phone
Pres	crit	oer r	nust	t con	nple	te al	l inf	forma	tion	above. It must be legible, correct	, and con	nplete	or fo	orm	n will be returned.
Pharr	nac	y NI	PI							Pharmacy fax		NDC	2		

Preferred agents are available without prior authorization (PA) when dosed within the established quantity limits.

PA is required for all non-preferred non-benzodiazepine sedative/hypnotics. Payment for a non-preferred agent will be authorized only for cases in which there is documentation of a previous trial and therapy failure with, at a minimum, three (3) preferred agents. Payment for non-preferred agent will be considered for an FDA approved or compendia indicated diagnosis for the requested drug when the following criteria are met: 1) Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and 2) A diagnosis of insomnia, 3) Medications with a side effect of insomnia are decreased in dose, changed to a short acting product, and/or discontinued, 4) Enforcement of good sleep hygiene is documented, 5) All medical, neurological, and psychiatric disease states causing chronic insomnia are being adequately treated with appropriate medication at therapeutic doses. 6) Will not be used concurrently with a benzodiazepine sedative/hypnotic agent. 7) In addition to the above criteria, requests for an orexin receptor antagonist will require documentation of a trial and therapy failure with at least one non-preferred agent prior to consideration of coverage. 8) Non-preferred alternative delivery systems will only be considered for cases in which the use of the alternative delivery system is medically necessary and there is a previous trial and therapy failure with a preferred alternative delivery system if available. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Preferred		Non-Preferred			
Eszopiclone		Ambien	🗌 Edluar	Ramelteon	🗌 Zolpidem ER
Zaleplon		Ambien CR	🗌 Lunesta	Rozerem	🗌 Zolpidem SL Tab
🗌 Zolpidem		Belsomra	Quviviq	🗌 Zolpimist	
		🗌 Dayvigo			
	Strength	Dosage Instruct	ions Quantity	Days Supply	
Diagnosis			– Date of Diagn	osis:	
Co-Morbid Con	ditions Contr	ibuting to Insomnia:			
	-	nents Tried:			
Requests for No		-	_		
Eszopiclone Tri	al: Dose:	Trial start dat	te: Tr	rial end date:	
Reason for Failure	e:				
Zaleplon Trial:	Dose:	Trial start date: _	Trial of	end date:	
Reason for Failure	2:				
Zolpidem Trial:	Dose:	Trial start date: _	Trial e	nd date:	
Reason for Failure	2:				

Request for Prior Authorization

SEDATIVE/HYPNOTICS-NON-BENZODIAZEPINE

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Yes Drug Name: Requests for Orexin Receptor Antagonist (in addition to t		
Trial of Non-Preferred Agent: Drug Name & Dose:		Trial end date:
Reason for Failure:		
Medical Necessity for alternative delivery system:		
Reason for use of Non-Preferred drug requiring prior approval:		
Attach lab results and other documentation as necessary (Re	quired).	
Prescriber signature (Must match prescriber listed above.)	Date of sub	omission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.